Loading...
PMCB logo

PharmaCyte Biotech, Inc.NasdaqCM:PMCB Stock Report

Market Cap US$8.2m
Share Price
US$0.73
My Fair Value
n/a
1Y-29.6%
7D-7.3%
Portfolio Value
​
View

PharmaCyte Biotech, Inc.

NasdaqCM:PMCB Stock Report

Market Cap: US$8.2m

PharmaCyte Biotech (PMCB) Stock Overview

A biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. More details

PMCB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($8M)

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Volatile share price over the past 3 months compared to the US market


PMCB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

PharmaCyte Biotech, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for PharmaCyte Biotech
Historical stock prices
Current Share PriceUS$0.73
52 Week HighUS$1.51
52 Week LowUS$0.63
Beta0.46
1 Month Change0.47%
3 Month Change11.42%
1 Year Change-29.62%
3 Year Change-76.54%
5 Year Change-96.10%
Change since IPO-99.67%

Recent News & Updates

Recent updates

Analysis Article • Mar 22

PharmaCyte Biotech (NASDAQ:PMCB) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 07

PharmaCyte Biotech says CEO to step down, announces strategic review of business

PharmaCyte Biotech (NASDAQ:PMCB) on Friday announced that its CEO Kenneth Waggoner had stepped down and said its board had authorized a business review committee to evaluate strategic opportunities for the company. Las Vegas, Nev. based PMCB is a biotech that is evaluating its live-cell encapsulation technology called Cell-in-a-Box for the potential development of therapies for cancer, diabetes and ascites, which is a condition in which fluid collects in the spaces within the abdomen. PMCB said its live-cell encapsulation technology involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or "cancer-killing" form. The company said it had appointed Joshua Silverman as interim CEO. The company also said it was assessing the concerns expressed by the U.S. FDA relating to the clinical hold placed on its investigational new drug application for the Cell-in-a-Box technology. PMCB stock +1.2% to $2.51 in early trading.
Seeking Alpha • Aug 15

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech (NASDAQ:PMCB) said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois’ director designees to its Board of Directors. (PMCB) rose ~4% before the bell. Iroquois’ director designees, Jonathan Schechter and Joshua Silverman, will join PharmaCyte’s reconstituted Board as independent directors, the company said. "We are nearing the end of our process to fulfill the FDA’s requests to enable the clinical hold to be lifted. To date, approximately 90% of the FDA’s requests have been completed or are in process with one major pig study remaining to be completed," said PharmaCyte’s Chief Executive Officer, Kenneth Waggoner. Iroquois has agreed to certain customary standstill provisions and will support the Board’s full slate of directors at the 2022 Annual Meeting.
Seeking Alpha • Jan 07

Is This A Good Time To Invest In PharmaCyte?

PharmaCyte has developed a cell encapsulation technique that allows foreign cells to be injected into the body without triggering an immune response. The company is using their encapsulation technique as a basis for developing treatments for diabetes and cancer. Currently, the company has no income stream. Financing is entirely from the sale of corporate stock.
Seeking Alpha • Aug 21

PharmaCyte Biotech: Buy The 'Dump'

I recommend that you nibble a few shares of PharmaCyte Biotech if interested in a “trade” or a very high-risk long-term buy-and-hold. Historically, the company (or its investors) has proved to be quite expert in self-promotion. Your entry price per share should be at or below $4.25. The direct offering is for 14 million shares plus up to 7 million shares, through warrants, for minimum proceeds of $70 million. Gross proceeds from NASDAQ offering for $15 million plus the $70 million direct offering will be used for Phase 2b clinical trials.

Shareholder Returns

PMCBUS BiotechsUS Market
7D-7.3%-4.9%-1.0%
1Y-29.6%28.1%23.3%

Return vs Industry: PMCB underperformed the US Biotechs industry which returned 30% over the past year.

Return vs Market: PMCB underperformed the US Market which returned 24.4% over the past year.

Price Volatility

Is PMCB's price volatile compared to industry and market?
PMCB volatility
PMCB Average Weekly Movement12.4%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

Stable Share Price: PMCB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PMCB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19962Josh Silvermanpharmacyte.com

PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company’s cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. It also develops CypCaps for pancreatic cancer and other solid cancerous tumors.

PharmaCyte Biotech, Inc. Fundamentals Summary

How do PharmaCyte Biotech's earnings and revenue compare to its market cap?
PMCB fundamental statistics
Market capUS$8.16m
Earnings (TTM)-US$7.49m
Revenue (TTM)n/a
0.0x
P/S Ratio
-1.0x
P/E Ratio

Is PMCB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PMCB income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$7.49m
Earnings-US$7.49m

Last Reported Earnings

Jan 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.70
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PMCB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/19 15:30
End of Day Share Price 2026/05/19 00:00
Earnings2026/01/31
Annual Earnings2025/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

PharmaCyte Biotech, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Edward WhiteH.C. Wainwright & Co.